Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Other Non-Current Liabilities (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Other Non-Current Liabilities for 2 consecutive years, with $2.8 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 8.06% to $2.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Dec 2025, down 8.06% year-over-year, with the annual reading at $2.8 million for FY2025, 8.06% down from the prior year.
  • Other Non-Current Liabilities hit $2.8 million in Q4 2025 for Prelude Therapeutics, down from $2.9 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $3.3 million in Q1 2024 to a low of $2.8 million in Q4 2025.